Том 3 (1129748), страница 62
Текст из файла (страница 62)
(2004) How to Win the Nobel Prize: An Unexpected Life in Science.Harvard University Press: Cambridge MA.Stillman В. & Stewart D. (eds) (2005) Molecular Approaches to ControllingCancer. Cold Spring Harbor Laboratory Press: Cold Spring Harbor.Weinberg R. A. (2007) The Biology of Cancer. Garland Science: New York.Рак как микроэволюционный процессAl-Hajj M., Becker M. W., Wicha M. et al.
(2004) Therapeutic implications ofcancer stem cells. Curr. Opin. Genet. Dev. 14: 43–47.Bielas J. H., Loeb K. R., Rubin B. P. et al. (2006) Human cancers express a mutatorphenotype. Proc. Natl. Acad. Sci. USA 103: 18238–18242.Cairns J. (1975) Mutation, selection and the natural history of cancer.
Nature255: 197–200.1938Часть 5. Клетки в контексте их совокупностиCampesi J. (2005) Senescent cells, tumor supression, and organismal aging: goodcitizens, bad neighbors. Cell 120: 513–522.Evan G. I. & Vousden K. H. (2001) Proliferation, cell cycle and apoptosis incancer. Nature 411: 342–348.Fialkow P. J. (1976) Clonal origin of human tumors. Biochim. Biophys. Acta.458: 283–321.Fidler I. J.
(2003) The pathogenesis of cancer metastasis: the 'seed and soil'hypothesis revisited. Nature Rev. Cancer 3: 453–458.Jones P. A. & Baylin S. B. (2002) The fundamental role of epigenetic events incancer. Nature Rev. Genet. 3: 415–428.Loeb L. A., Loeb K. R. & Anderson J. P. (2003) Multiple mutations and cancer.Proc.
Natl. Acad. Sci. USA 100: 776–781.Lowe S. W., Cepero E. & Evan G. (2004) Intrinsic tumour suppression. Nature432: 307–315.Nowell P. C. (1976) The clonal evolution of tumor cell populations. Science194: 23–28.Pardal R., Clarke M. F. & Morrison S. J. (2003) Applying the principles of stemcell biology to cancer. Nature Rev. Cancer 3: 895–902.Sjoblom T., Jones S., Wood L. D. et al. (2006) The consensus coding sequencesof human breast and colorectal cancers.
Science 314: 268–274.Thiery J. P. (2002) Epithelial-mesenchymal transitions in tumour progression.Nature Rev. Cancer 2: 442–454.Tlsty T. D. & Coussens L. M. (2006) Tumor Stroma and Regulation of CancerDevelopment. Annu. Rev. Pathol. Mech. Dis. 1: 119–150.Ward R. J. & Dirks P. B. (2007) Cancer stem cells: at the headwaters of tumordevelopment. Annu. Rev. Pathol. Mech.
Dis. 2: 175–189.Профилактика ракаAmes B., Durston W. E., Yamasaki E. & Lee F. D. (1973) Carcinogens aremutagens: a simple test system combining liver homogenates for activation and bacteriafor detection. Proc. Natl. Acad. Sci. USA 70: 2281–2285.Berenblum I. (1954) A speculative review: the probable nature of promotingaction and its significance in the understanding of the mechanism of carcinogenesis.Cancer Res. 14: 471–477.Cairns J. (1985) The treatment of diseases and the war against cancer.
Sci. Am.253: 51–59.Doll R. (1977) Strategy for detection of cancer hazards to man. Nature 265:589–597.Doll R. & Peto R. (1981) The causes of cancer: quantitative estimates of avoidablerisks of cancer in the United States today. J. Natl. Cancer Inst. 66: 1191–1308.Hsu I. С., Metcalf R. A., Sun T. et al. (1991) Mutational hotspot in the p53 genein human hepatocellular carcinomas. Nature 350: 427–428.Newton R., Beral V.
& Weiss R. A. (eds) (1999) Infections and Human Cancer.Cold Spring Harbor Laboratory Press: Cold Spring Harbor.Peto J. (2001) Cancer epidemiology in the last century and the next decade.Nature 411: 390–395.Поиск генов, связанных с раковыми заболеваниямиDavies H., Bignell G. R., Сох С. et al. (2002) Mutations of the BRAF gene inhuman cancer. Nature 417: 949–954.Литература 1939Easton D. F., Pooley K. A., Dunning A. M. et al. (2007) Genome-wide associationstudy identifies novel breast cancer susceptibility loci.
Nature 447: 1087–1095.Feinberg A. P. (2007) Phenotypic plasticity and the epigenetics of human disease.Nature 447: 433–440.Herman J. G. & Baylin S. B. (2003) Gene silencing in cancer in association withpromoter hypermethylation. N. Engl. J. Med. 349: 2042–2054.Lowe S. W., Cepero E. & Evan G.
(2004) Intrinsic tumour suppression. Nature432: 307–315.Mitelman F., Johansson В. & Mertens F. (2007) The impact of translocationsand gene fusions on cancer causation. Nature Rev. Cancer 7: 233–245.Pinkel D. & Albertson D. G. (2005). Comparative genomic hybridization.
Annu.Rev. Genomics Hum. Genet. 6: 331–354.Rowley J. D. (2001) Chromosome translocations: dangerous liasisons revisited.Nature Rev. Cancer 1: 245–250.The Wellcome Trust Case Control Consortium (2007) Genome-wide associationstudy of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447: 661–683.Westbrook T. F., Stegmeier F. & Elledge S. J. (2005) Dissecting cancer pathways andvulnerabilities with RNAi.
Cold Spring Harb. Symp. Quant. Biol. 70: 435–444.Молекулярные основы поведения раковых клетокArtandi S. E. & DePinho R. A. (2000) Mice without telomerase: what can theyteach us about human cancer? Nature Med. 6: 852–855.Brown J. M. & Attardi L. D. (2005) The role of apoptosis in cancer developmentand treatment response. Nature Rev. Cancer 5: 231–237.Chambers A. F., Naumov G. N., Vantyghem S. & Tuck A. B. (2000) Molecularbiology of breast cancer metastasis: clinical implications of experimental studies onmetastatic inefficiency.
Breast Cancer Res. 2: 400–407.Edwards P. A. W. (1999) The impact of developmental biology on cancer research:an overview. Cancer Metastasis Rev. 18: 175–180.Futreal P. A., Coin L., Marshall M. et al. (2004) A census of human cancer genes.Nature Rev. Cancer 4: 177–183.Hanahan D.
& Weinberg R. A. (2000) The hallmarks of cancer. Cell 100: 57–70.Hoffman R. M. (2005) The multiple uses of fluorescent proteins to visualize cancerin vivo. Nature Rev. Cancer 5: 796–806.Kinzler K. W. & Vogelstein В. (1996) Lessons from hereditary colorectal cancer.Cell 87: 159–170.Levine A. J., Hu W.
& Feng Z. (2006) The P53 pathway: what questions remainto be explored? Cell Death Differ. 13: 1027–1036.Macleod K. F & Jacks T. (1999) Insights into cancer from transgenic mousemodels. J. Pathol. 187: 43–60.Mani S. A., Yang J., Brooks M. et al. (2007) Mesenchyme Forkhead 1 (FOXC2)plays a key role in metastasis and is associated with aggressive basal-like breast cancers.Proc. Natl. Acad. Sci. USA 104: 10069–10074.Mueller M. M. & Fusenig N. E. (2004) Friends or foes—bipolar effects of thetumour stroma in cancer. Nature Rev.
Cancer 4: 839–849.Plas D. R. & Thompson C. B. (2005) Akt-dependent transformation: there is moreto growth than just surviving. Oncogene 24: 7435–7442.1940Часть 5. Клетки в контексте их совокупностиRidley A. (2000) Molecular switches in metastasis. Nature 406: 466–467.Shaw R. J. & Cantley L. C. (2006) Ras, PI(3)K and mTOR signalling controlstumour cell growth. Nature 441: 424–430.Sherr C. J.
(2006) Divorcing ARF and p53: an unsettled case. Nature Rev.Cancer 6: 663–673.Vogelstein В. & Kinzler K. W. (2004) Cancer genes and the pathways they control.Nature Med. 10: 789–799.Weinberg R. A. (1995) The retinoblastoma protein and cell-cycle control. Cell81: 323–330.Лечение рака: сегодня и завтраAlizadeh A. A., Eisen M. B., Davis R. E. et al. (2000). Distinct types of diffuse largeB-cell lymphoma identified by gene expression profiling. Nature 403: 503–511.Baselga J.
& Albanell J. (2001) Mechanism of action of anti-HER2 monoclonalantibodies. Annu. Oncol. 12: S35–S41.Druker B. J. & Lydon N. B. (2000) Lessons learned from the development of an abltyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105: 3–7.Folkman J. (1996) Fighting cancer by attacking its blood supply. Sci.
Am. 275:150–154.Golub T. R., Slonim D. K., Tamayo P. et al. (1999) Molecular classification ofcancer: class discovery and class prediction by gene expression monitoring. Science286: 531–537.Huang P. & Oliff A. (2001) Signaling pathways in apoptosis as potential targetsfor cancer therapy. Trends Cell Biol. 11: 343–348.Garraway L. A.
& Sellers W. R. (2006) Lineage dependency and lineage-survivaloncogenes in human cancer. Nature Rev. Cancer 6: 593–602.Jonkers J. & Berns A. (2004) Oncogene addiction: sometimes a temporary slavery.Cancer Cell 6: 535–538.Jain R. K.
(2005) Normalization of tumor vasculature: an emerging concept inantiangiogenic therapy. Science 307: 58-62.Kim R., Emi M. & Tanabe K. (2007) Cancer immunoediting from immunesurveillance to immune escape. Immunology 121: 1–14.Madhusudan S. & Middleton M. R. (2005) The emerging role of DNA repairproteins as predictive, prognostic and therapeutic targets in cancer. Cancer TreatRev. 31: 603–617.Roninson I. B., Abelson H. T., Housman D. E. et al. (1984) Amplification ofspecific DNA sequences correlates with multi-drug resistance in Chinese hamster cells.Nature 309: 626–628.Sarkadi B., Homolya L., Szakacs G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
